Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?

Basit Öğe Kaydı
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorInal, Ali
dc.contributor.authorZinciroglu, S.
dc.contributor.authorCit, Murtaza
dc.contributor.authorCil, Timucin
dc.date.accessioned2024-04-24T17:24:55Z
dc.date.available2024-04-24T17:24:55Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim of the study: Lung cancer is the most common malignancy, accounting for one-third of all deaths from cancer. Some studies have shown that low molecular weight heparin (LMWH) significantly prolongs the survival of patients with non-small cell lung cancer (NSCLC). The aim of this study was to determine the effects of treating inoperable stage III NSCLC with LMWH in addition to concurrent chemoradiotherapy. Material and methods: Eighty-two patients with inoperable stage III NSCLC were evaluated at Dicle University's Medical Oncology Department between 2005 and 2010. All patients were treated with concurrent chemoradiotherapy (CRT) with or without LMWH (enoxaparin 4000 IU/day) depending on the patient's risk of thrombosis. The primary objectives were to determine disease-free survival (DES) and overall survival (OS) for patients treated with LMWH. Results: A total of 38 patients in the LMWH negative group and 44 patients in the LMWH positive group were included in the study. The median OS was 11.2 months for the enoxaparin recipients and 12.7 months for the non-enoxaparin group (p = 0.4). The median DES was 9.3 months with CRT alone and 10.0 months with CRT plus enoxaparin (p = 0.9). The one-year OS rates were 47% and 34% for groups treated with CRT and enoxaparin plus CRT, respectively, while the two-year OS rates were 23% and 21%, respectively. No significant difference was noted between the two groups in terms of grade 3-4 hematologic toxicity and mucositis (p = 0.3). Conclusions: This study did not demonstrate improvements in survival for patients with NSCLC treated with enoxaparin. LMWH's positive contribution is still controversial.en_US
dc.identifier.doi10.5114/wo.2012.31771
dc.identifier.endpage419en_US
dc.identifier.issn1428-2526
dc.identifier.issue5en_US
dc.identifier.pmid23788920
dc.identifier.scopus2-s2.0-84870164484
dc.identifier.scopusqualityQ2
dc.identifier.startpage416en_US
dc.identifier.urihttps://doi.org/10.5114/wo.2012.31771
dc.identifier.urihttps://hdl.handle.net/11468/19880
dc.identifier.volume16en_US
dc.identifier.wosWOS:000311650100009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTermedia Publishing House Ltden_US
dc.relation.ispartofWspolczesna Onkologia-Contemporary Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectLow Molecular Weight Heparinen_US
dc.subjectChemoradiotherapyen_US
dc.titleCan LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?en_US
dc.titleCan LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu